Xaira, founded in 2023 and headquartered in San Francisco, California, United States, is an AI-driven drug discovery platform that accelerates development through advanced biological and clinical data generation. The company has raised $1 billion, including a $1 billion Series D in April 2024, led by Arch Venture Partners and Foresite Labs, achieving unicorn status in just one year and three months. Xaira leverages AI for translational and fundamental research, streamlining drug development processes and enhancing R&D productivity for biotech and life sciences innovation.